Overview

Pharmacokinetic Study to Determine Time to Steady-state

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.
Phase:
Phase 2
Details
Lead Sponsor:
Clarus Therapeutics, Inc.
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate